Latest progress

Recently, Salubris announced that its self-developed oral small molecule immunosuppressant SAL0119 has been approved by NMPA to carry out clinical trials for the treatment of ankylosing spondylitis (AS) and rheumatoid arthritis (RA).

Both AS and RA have the characteristics of long course of disease, easy to relapse, and lifelong treatment needed for most patients, which seriously impacts the physical and mental health and quality of life of patients.

SAL0119 showed good efficacy and safety in preclinical studies. If it is successfully developed and approved for marketing, it will provide more options for AS and RA patients and meet the unmet clinical needs.

Prevalence of AS and RA in China

The prevalence of ankylosing spondylitis (AS) in China is about 0.3%. The age of onset was 15 to 40 years old, and the peak age was 18 to 35 years old.

The incidence of rheumatoid arthritis (RA) is about 0.42%, and the total population affected by RA is about 5 million. RA can occur at any age. With the prolongation of the disease course, the incidence of disability and functional limitation increases, the disability rate of patients with disease duration ≥15 years was 61.3%.